Demerol (meperidine) is a weaker opioid than morphine. When injected, it takes about 75 mg of Demerol to match the pain relief of 10 mg of morphine, making it roughly one-seventh as potent. When taken by mouth, the gap widens further: 300 mg of oral Demerol equals just 30 mg of oral morphine, a 10-to-1 ratio.
Despite being less potent milligram-for-milligram, Demerol can still produce significant pain relief, sedation, and euphoria. It was once one of the most commonly prescribed opioids in hospitals, but its use has dropped sharply over the past two decades because of a dangerous byproduct the body creates when breaking it down.
How Demerol Compares to Other Opioids
Receptor-binding studies offer another way to measure an opioid’s raw strength. Researchers rank drugs by how tightly they latch onto the brain’s primary pain receptor (the mu-opioid receptor). Demerol falls into the weakest binding category, alongside codeine and tramadol, with a binding constant above 100 nM. Morphine, oxycodone, fentanyl, and methadone all bind more tightly, sitting in the 1 to 100 nM range. The strongest binders, like hydromorphone and sufentanil, grip the receptor at concentrations below 1 nM.
In practical terms, this means Demerol requires higher and more frequent doses to control the same level of pain that a smaller amount of morphine or hydromorphone could handle. Its action also kicks in slightly faster than morphine but wears off slightly sooner, so the window of relief is narrower.
Why Demerol Fell Out of Favor
The biggest problem with Demerol isn’t its strength but what happens after the body metabolizes it. Your liver converts meperidine into a byproduct called normeperidine. While the painkiller itself clears from your system in 2 to 5 hours, normeperidine lingers for 15 to 30 hours. With repeated doses, it accumulates.
Normeperidine is neurotoxic. As levels build up, it can cause tremors, muscle twitches, dilated pupils, hyperactive reflexes, hallucinations, and seizures. This excitatory syndrome is the opposite of what you’d expect from an opioid, and it doesn’t respond to the standard opioid-reversal treatments used in emergencies. The risk climbs with every additional dose, which is why Demerol is now generally restricted to very short courses, typically no more than 48 hours.
People with reduced kidney function face an even higher risk. When the kidneys can’t efficiently clear normeperidine, it accumulates faster. The American Academy of Family Physicians recommends against using Demerol entirely in patients with advanced kidney disease. It also appears on the Beers Criteria, a widely used list of medications that older adults should avoid, specifically because of the risk of neurotoxicity and delirium.
Where Demerol Is Still Used
One area where Demerol still has a niche is treating post-operative shivering and medication-induced rigors. Unlike most opioids, meperidine has additional properties beyond simple pain receptor activation: it affects serotonin and norepinephrine pathways and has anticholinergic effects. This combination makes it unusually effective at stopping uncontrollable shaking after surgery or during certain intravenous drug infusions. A small intravenous dose of around 25 mg is often enough to stop post-surgical shivering, and for rigors caused by other medications, effective doses typically range from 25 to 60 mg.
Demerol was also once a staple for labor pain, given as an intramuscular injection of about 75 mg. That practice has declined significantly. The drug crosses the placenta, and normeperidine accumulates in the fetus with a half-life of over 20 hours. Newborns exposed to Demerol during labor show higher rates of respiratory depression and disrupted feeding behaviors. In studies, half of exposed infants failed to breastfeed normally and cried more during the newborn period.
Serotonin Syndrome Risk
Demerol carries a risk that most other opioids don’t share to the same degree. Because it affects serotonin pathways, combining it with other serotonin-boosting medications can trigger serotonin syndrome, a potentially life-threatening reaction. This is especially dangerous with a class of antidepressants called MAO inhibitors, where the combination is considered absolutely contraindicated.
Serotonin syndrome can develop rapidly and produces a cluster of symptoms: agitation, confusion, or even coma; a racing heart with unstable blood pressure and high fever; muscle rigidity and exaggerated reflexes; and nausea, vomiting, or diarrhea. The risk also exists with more commonly prescribed antidepressants like SSRIs and SNRIs, though to a lesser degree than with MAO inhibitors.
Addiction and Abuse Potential
Like all opioids, Demerol produces euphoria and carries a real risk of dependence and addiction. Its relatively fast onset made it appealing for misuse, and historically it was one of the most commonly diverted prescription opioids in hospital settings. The same properties that make it act quickly also mean the high fades sooner, which can drive more frequent dosing and faster development of tolerance.
Today, most hospitals have either removed Demerol from their formularies entirely or placed strict limits on its use. When it is prescribed, it’s typically reserved for patients who can’t tolerate other opioids or for the specific anti-shivering application where it remains uniquely effective. For general pain management, stronger and safer alternatives like morphine, hydromorphone, and oxycodone have largely replaced it.